Shandong Sito Bio-technology Co

Shandong Sito Bio-technology Co Dividend Coverage

The Dividend Coverage Ratio of Shandong Sito Bio-technology Co (300583.SZ) as of Nov 3, 2026 is -18.23. In the previous year, Dividend Coverage Ratio was -0.97 — a change of 1,782.33% (lower).

Dividend Coverage

-18.23

YoY

1,782.33%

Last updated:

Dividend Coverage Ratio of Shandong Sito Bio-technology Co is 2025 -18.23 . Dividend Coverage Ratio of Shandong Sito Bio-technology Co was 2024 -0.97 . It decreases by 1,782.33% lower compared to the previous year.

The Shandong Sito Bio-technology Co Dividend Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend Coverage
Date
Dividend Coverage
Jan 1, 2017
8.60 CNY
Jan 1, 2018
12.19 CNY
Jan 1, 2019
3.78 CNY
Jan 1, 2020
-32.20 CNY
Jan 1, 2022
24.38 CNY
Jan 1, 2023
25.57 CNY
Jan 1, 2024
-0.97 CNY
Jan 1, 2025
-18.23 CNY
The Shandong Sito Bio-technology Co Dividend Coverage history
YEARDividend CoverageYoY
-18.23+1,782.33%
-0.97-103.79%
25.57+4.90%
24.38-175.71%
-32.20-951.59%
3.78-68.98%
12.19+41.74%
8.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shandong Sito Bio-technology Co Stock analysis

What does Shandong Sito Bio-technology Co do? Shandong Sito Bio-technology Co., Ltd. generates revenue through three product segments. The Steroid Raw Materials segment produces steroid raw materials like androstenedione and 9-hydroxyandrostenedione using genetic engineering and microbial transformation technology. The Steroidal Finished Drug segment and Non-Steroidal Finished Drug segment are operated via its subsidiary, offering finished pharmaceutical products. The company's primary customers are pharmaceutical manufacturers requiring raw materials and finished drugs for further processing. The Steroid Raw Materials segment focuses on manufacturing key compounds such as androstenedione, hydroxyprogesterone, and 9-hydroxyandrostenedione. These materials are essential for the production of various steroid-based pharmaceuticals. The Steroidal Finished Drug segment provides ready-to-use pharmaceutical products, while the Non-Steroidal Finished Drug segment offers non-steroid alternatives, targeting different medical needs. Shandong Sito serves pharmaceutical companies that need raw materials for steroid-based drugs and finished drugs for distribution. The Steroid Raw Materials segment supplies critical inputs for steroid pharmaceutical production, while the Steroidal and Non-Steroidal Finished Drug segments cater to end-market demand for completed pharmaceutical products. The company's operations are centered around biotechnology-driven manufacturing of pharmaceutical ingredients and finished drugs. Shandong Sito Bio-technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shandong Sito Bio-technology Co stock

Dividend Coverage Ratio of Shandong Sito Bio-technology Co is -18.23 in 2025.

Dividend Coverage Ratio of Shandong Sito Bio-technology Co changed from -0.97 to -18.23, representing a 1,782.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Shandong Sito Bio-technology Co since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Shandong Sito Bio-technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Shandong Sito Bio-technology Co

All Key Metrics — Shandong Sito Bio-technology Co